Terms: = Sarcomas AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
805 results:
1. Temporal trends and regional variability in braf and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-targeted therapy with braf-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract] [Full Text] [Related]
3. braf V600E Mutation in Malignant Melanoma-A Romanian Research Experience.
Avădănei ER; Căruntu ID; Nucă I; Balan R; Lozneanu L; Giusca SE; Amalinei C
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541077
[No Abstract] [Full Text] [Related]
4. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract] [Full Text] [Related]
5. Identification of Germline
Pires C; Saramago A; Moura MM; Li J; Donato S; Marques IJ; Belo H; Machado AC; Cabrera R; Grünewald TGP; Leite V; Cavaco BM
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396644
[TBL] [Abstract] [Full Text] [Related]
6. PD-L1 expression and its correlation with clinicopathological and molecular characteristics in Chinese patients with non-small cell lung cancer.
Guo J; Yuan H; Zhu Y; Che Z; Zhang B; Zhang D; Zhou Y; Xiong L
Medicine (Baltimore); 2024 Feb; 103(8):e36770. PubMed ID: 38394518
[TBL] [Abstract] [Full Text] [Related]
7. CD30 expression in an emerging group of mesenchymal spindle cell neoplasms with ALK fusion detected by flow cytometry and immunohistochemistry.
Iwakoshi A; Kikui H; Nakashima R; Goto Y; Ichikawa D; Sasaki E; Sekimizu M; Hattori H; Maeda N
Genes Chromosomes Cancer; 2024 Feb; 63(2):e23228. PubMed ID: 38380728
[TBL] [Abstract] [Full Text] [Related]
8. Clinical features and mutation analysis of class 1/2/3 braf mutation colorectal cancer.
Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
[TBL] [Abstract] [Full Text] [Related]
9. Is there a prognostic difference among stage I lung adenocarcinoma patients with different braf-mutation status?
Ma SS; Wang RR; Peng Q; Liu Y; Qian JY; Li MJ; Li K; Huang ZY; Wu LL; Xie D
Thorac Cancer; 2024 Mar; 15(9):715-721. PubMed ID: 38362771
[TBL] [Abstract] [Full Text] [Related]
10. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
[TBL] [Abstract] [Full Text] [Related]
12. [Progress of braf Gene Alteration in Non-small Cell Lung Cancer].
Deng L; Yang Y; Huang J
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):73-80. PubMed ID: 38296628
[TBL] [Abstract] [Full Text] [Related]
13. Exploring the role of sporadic braf and KRAS mutations during colorectal cancer pathogenesis: A spotlight on the contribution of the endosome-lysosome system.
Tang J; Lam GT; Brooks RD; Miles M; Useckaite Z; Johnson IR; Ung BS; Martini C; Karageorgos L; Hickey SM; Selemidis S; Hopkins AM; Rowland A; Vather R; O'Leary JJ; Brooks DA; Caruso MC; Logan JM
Cancer Lett; 2024 Mar; 585():216639. PubMed ID: 38290660
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and safety of 'Second Adjuvant' therapy with braf/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor AM; McKeown J; Dimitriou F; Jacques SK; Zimmer L; Allayous C; Yeoh HL; Haydon A; Ressler JM; Galea C; Woodford R; Kahler K; Hauschild A; Festino L; Hoeller C; Schwarze JK; Neyns B; Wicky A; Michielin O; Placzke J; Rutkowski P; Johnson DB; Lebbe C; Dummer R; Ascierto PA; Lo S; Long GV; Carlino MS; Menzies AM
Eur J Cancer; 2024 Mar; 199():113561. PubMed ID: 38278009
[TBL] [Abstract] [Full Text] [Related]
15. Recent Advances in the Diagnosis, Pathogenesis, and Management of Myxoinflammatory Fibroblastic Sarcoma.
Nishio J; Nakayama S; Aoki M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256198
[TBL] [Abstract] [Full Text] [Related]
16. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
Benhima N; Belbaraka R; Langouo Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):69-73. PubMed ID: 38193381
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
18. Sequential immunotherapy and targeted therapy for metastatic braf V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
[TBL] [Abstract] [Full Text] [Related]
19. Colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
[TBL] [Abstract] [Full Text] [Related]
20. Repurposing Metabolic Inhibitors in the Treatment of Colon Adenocarcinoma Patient-Derived Models.
Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
[TBL] [Abstract] [Full Text] [Related]
[Next]
